Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Am J Obstet Gynecol. 2014 Oct 19;212(4):479.e1–479.e10. doi: 10.1016/j.ajog.2014.10.026

Figure 1.

Figure 1

Metformin inhibits growth and activates AMPK in ovarian cancer cells. (A) MTT proliferation assays showing that Ovcar-5, Kras/PTEN, SKOV3ip1, Kuramochi, HeyA8 and IOSE cell lines treated with 10, 20 or 40 mM metformin exhibit a dose-dependent reduction in proliferation. Bars represent fold change in proliferation. In 4 out of 6 cell lines the reduction in proliferation is statistically significant (p <0.05) with all metformin concentrations when compared to control, the exceptions are the Kuramochi and IOSE cell lines. (B) Western blots. Protein expression of LKB1 in cell lines. (C) Western blots. Protein expression of phosphorylated (activated) AMPK (Thr 172). B-actin done for each blot, but only shown for the IOSE blot. The indicated cell lines were serum-starved for 24 hours and then treated with 10, 20 or 40 mM metformin or vehicle for 24 hours.